Therapeutic options for transfusion related acute lung injury; the potential of the G2A receptor

Current Pharmaceutical Design

Volumn 18, Issue 22, 2012, Pages 3255-3259

  Ellison, Michael A ^a   Ambruso, Daniel R ^a,b   Silliman, Christopher C ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b Children's Hospital Colorado   (United States)

Author keywords

Clathrin mediated endocytosis; G protein coupled receptor; G2A receptor; Lysophosphatidylcholine; Lysophospholipid; Transfusion related acute lung injury

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CALCIUM ION; CD11B ANTIGEN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 2A; LEUKOCYTE ANTIBODY; LYSOPHOSPHATIDYLCHOLINE DERIVATIVE; LYSOPHOSPHOLIPID; PHOSPHATIDYLCHOLINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; BLOOD AUTOTRANSFUSION; BLOOD STORAGE; CYTOPLASM; ERYTHROCYTE TRANSFUSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOTHERAPY; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSFUSION RELATED ACUTE LUNG INJURY;

EID: 84862579670     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023255     Document Type: Article

References (48)

1. Boxer LA, Axtell R, Suchard S. The role of the neutrophil in inflammatory diseases of the lung. Blood Cells 1990; 16(1): 25-40.
2. Henson PM, Johnston RB, Jr. Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins. J Clin Invest 1987; 79(3): 669-74.
3. Vercellotti GM, Yin HQ, Gustafson KS, Nelson RD, Jacob HS. Platelet-activating factor primes neutrophil responses to agonists: role in promoting neutrophil-mediated endothelial damage. Blood 1988; 71(4): 1100-7.
4. Wedmore CV, Williams TJ. Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature 1981; 289(5799): 646-50.
5. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320(6): 365-76.
6. Silliman CC. The two-event model of transfusion-related acute lung injury. Crit Care Med 2006; 34(5 Suppl): S124-31.
7. Wyman TH, Bjornsen AJ, Elzi DJ, et al. A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release. Am J Physiol Cell Physiol 2002; 283(6): C1592-603.
8. Doerschuk CM. Mechanisms of leukocyte sequestration in inflamed lungs. Microcirculation 2001; 8(2): 71-88.
9. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood 2005; 105(6): 2266-73.
10. Hallett MB, Lloyds D. Neutrophil priming: the cellular signals that say 'amber' but not 'green'. Immunol Today 1995; 16(6): 264-8.
11. Condliffe AM, Kitchen E, Chilvers ER. Neutrophil priming: pathophysiological consequences and underlying mechanisms. Clin Sci (Lond) 1998; 94(5): 461-71.
12. Aida Y, Pabst MJ. Neutrophil responses to lipopolysaccharide. Effect of adherence on triggering and priming of the respiratory burst. J Immunol 1991; 146(4): 1271-6.
13. Guthrie LA, McPhail LC, Henson PM, Johnston RB, Jr. Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. Evidence for increased activity of the superoxide- producing enzyme. J Exp Med 1984; 160(6): 1656-71.
14. Damaj BB, McColl SR, Neote K, Hebert CA, Naccache PH. Diverging signal transduction pathways activated by interleukin 8 (IL-8) and related chemokines in human neutrophils. IL-8 and Groalpha differentially stimulate calcium influx through IL-8 receptors A and B. J Biol Chem 1996; 271(34): 20540-4.
15. Corey SJ, Rosoff PM. Unsaturated fatty acids and lipoxygenase products regulate phagocytic NADPH oxidase activity by a nondetergent mechanism. J Lab Clin Med 1991; 118(4): 343-51.
16. Silliman CC, Thurman GW, Ambruso DR. Stored blood components contain agents that prime the neutrophil NADPH oxidase through the platelet-activating-factor receptor. Vox Sang 1992; 63(2): 133-6.
17. Heuer HO, Casals-Stenzel J, Muacevic G, Weber KH. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor. J Pharmacol Exp Ther 1990; 255(3): 962-8.
18. Silliman CC, Johnson CA, Clay KL, Thurman GW, Ambruso DR. Compounds biologically similar to platelet activating factor are present in stored blood components. Lipids 1993; 28(5): 415-8.
19. Silliman CC, Clay KL, Thurman GW, Johnson CA, Ambruso DR. Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase. J Lab Clin Med 1994; 124(5): 684-94.
20. Silliman CC, Elzi DJ, Ambruso DR, et al. Lysophosphatidylcholines prime the NADPH oxidase and stimulate multiple neutrophil functions through changes in cytosolic calcium. J Leukoc Biol 2003; 73(4): 511-24.
21. Silliman CC, Dickey WO, Paterson AJ, et al. Analysis of the priming activity of lipids generated during routine storage of platelet concentrates. Transfusion 1996; 36(2): 133-9.
22. Ambruso DR, Thurman G, Tran K, et al. Generation of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions. Transfusion 2011; 51(6): 1220-7.
23. Silliman CC, Moore EE, Kelher MR, Khan SY, Gellar L, Elzi DJ. Identification of lipids that accumulate during the routine storage of prestorage leukoreduced red blood cells and cause acute lung injury. Transfusion 2011.
24. Vlaar AP, Kulik W, Nieuwland R, et al. Accumulation of bioactive lipids during storage of blood products is not cell but plasma derived and temperature dependent. Transfusion 2011.
25. Kitchen E, Rossi AG, Condliffe AM, Haslett C, Chilvers ER. Demonstration of reversible priming of human neutrophils using platelet-activating factor. Blood 1996; 88(11): 4330-7.
26. Silliman CC, Paterson AJ, Dickey WO, et al. The association of biologically active lipids with the development of transfusionrelated acute lung injury: a retrospective study. Transfusion 1997; 37(7): 719-26.
27. Silliman CC, Bjornsen AJ, Wyman TH, et al. Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion 2003; 43(5): 633-40.
28. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al. Transfusionrelated acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101(2): 454-62.
29. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985; 25(6): 573-7.
30. Popovsky MA, Chaplin HC, Jr., Moore SB. Transfusion-related acute lung injury: a neglected, serious complication of hemotherapy. Transfusion 1992; 32(6): 589-92.
31. Flesch BK, Neppert J. Transfusion-related acute lung injury caused by human leucocyte antigen class II antibody. Br J Haematol 2002; 116(3): 673-6.
32. Kopko PM, Popovsky MA, MacKenzie MR, Paglieroni TG, Muto KN, Holland PV. HLA class II antibodies in transfusion-related acute lung injury. Transfusion 2001; 41(10): 1244-8.
33. Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis 1983; 128(1): 185-9.
34. Yomtovian R, Kline W, Press C, et al. Severe pulmonary hypersensitivity associated with passive transfusion of a neutrophil-specific antibody. Lancet 1984; 1(8371): 244-6.
35. Silliman CC. Transfusion-related acute lung injury. Transfus Med Rev 1999; 13(3): 177-86.
36. Covin RB, Ambruso DR, England KM, et al. Hypotension and acute pulmonary insufficiency following transfusion of autologous red blood cells during surgery: a case report and review of the literature. Transfus Med 2004; 14(5): 375-83.
37. Silliman CC, Voelkel NF, Allard JD, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest 1998; 101(7): 1458-67.
38. Kabarowski JH, Zhu K, Le LQ, Witte ON, Xu Y. Lysophosphatidylcholine as a ligand for the immunoregulatory receptor G2A. Science 2001; 293(5530): 702-5.
39. Witte ON, Kabarowski JH, Xu Y, Le LQ, Zhu K. Retraction. Science 2005; 307(5707): 206.
40. Wang L, Radu CG, Yang LV, Bentolila LA, Riedinger M, Witte ON. Lysophosphatidylcholine-induced surface redistribution regulates signaling of the murine G protein-coupled receptor G2A. Mol Biol Cell 2005; 16(5): 2234-47.
41. Frasch SC, Zemski-Berry K, Murphy RC, Borregaard N, Henson PM, Bratton DL. Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A. J Immunol 2007; 178(10): 6540-8.
42. Yan JJ, Jung JS, Lee JE, et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 2004; 10(2): 161-7.
43. Khan SY, McLaughlin NJ, Kelher MRA, et al. Lysophosphatidylcholines activate G2A inducing G(alphai)-/G(alphaq/)- Ca(2)(+) flux, G(betagamma)-Hck activation and clathrin/beta-arrestin- 1/GRK6 recruitment in PMNs. Biochem J 2010; 432(1): 35-45.
44. Reil A, Keller-Stanislawski B, Gunay S, Bux J. Specificities of leucocyte alloantibodies in transfusion-related acute lung injury and results of leucocyte antibody screening of blood donors. Vox Sang 2008; 95(4): 313-7.
45. Insunza A, Romon I, Gonzalez-Ponte ML, et al. Implementation of a strategy to prevent TRALI in a regional blood centre. Transfus Med 2004; 14(2): 157-64.
46. Sheppard GS, Pireh D, Carrera GM, Jr., et al. 3-(2-(3- Pyridinyl)thiazolidin-4-oyl)indoles, a novel series of platelet activating factor antagonists. J Med Chem 1994; 37(13): 2011-32.
47. Burke JE, Dennis EA. Phospholipase A2 biochemistry. Cardiovasc Drugs Ther 2009; 23(1): 49-59.
48. Jackson SK, Abate W, Tonks AJ. Lysophospholipid acyltransferases: novel potential regulators of the inflammatory response and target for new drug discovery. Pharmacol Ther 2008; 119(1): 104-14.